Searl gets DRAP approval for biosimilar drug

MG News | December 14, 2023 at 12:06 PM GMT+05:00

0:00

December 14, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, the company's latest filing on the PSX showed today.

This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan, the notice reads.

The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan, it said.

The company said that this development aligns with its commitment to diversifying its product portfolio, thereby enhancing the quality of earnings and shareholders' value.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	134,299.77 290.06M	0.39% 517.42
ALLSHR	84,018.16 764.12M	0.48% 402.35
KSE30	40,814.29 132.59M	0.33% 132.52
KMI30	192,589.16 116.24M	0.49% 948.28
KMIALLSHR	56,072.25 387.69M	0.32% 180.74
BKTi	36,971.75 19.46M	-0.05% -16.94
OGTi	28,240.28 6.19M	0.21% 58.78

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	118,140.00	119,450.00 115,635.00	4270.00 3.75%
BRENT CRUDE	70.63	70.71 68.55	1.99 2.90%
RICHARDS BAY COAL MONTHLY	97.50	0.00 0.00	1.10 1.14%
ROTTERDAM COAL MONTHLY	108.75	108.75 108.75	0.40 0.37%
USD RBD PALM OLEIN	998.50	998.50 998.50	0.00 0.00%
CRUDE OIL - WTI	68.75	68.77 66.50	2.18 3.27%
SUGAR #11 WORLD	16.56	16.60 16.20	0.30 1.85%